Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Still Rules Immuno-Oncology, But For How Long?

Oct 27 2016

• By Emily Hayes

Related Content

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update

Oct 20 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch

Oct 25 2016

AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS

Oct 27 2016

Bristol Stresses Cost Control Despite Strong Earnings Quarter

Oct 27 2016

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

AstraZeneca PLC

Additional Topics

ImmunoOncology Sales & Earnings Approvals Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window